sign in sign up
<<
Home , Goserelin, Histrelin

Cigna National Formulary Coverage Policy

Prior Authorization -Releasing Hormone Agonists Implant - Zoladex® ( subcutaneous implant)

Table of Contents Product Identifer(s)

National Formulary Medical Necessity ...... 1 66292 Conditions Not Covered...... 2 Background ...... 2 References ...... 3 Revision History ...... 3

INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

Cigna covers goserelin acetate (Zoladex®) as medically necessary when the following criteria are met for FDA Indications or Other Uses with Supportive Evidence:

Prior Authorization is recommended for prescription benefit coverage of Zoladex. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of individuals treated with Zoladex as well as the monitoring required for adverse events and long-term efficacy, approval requires this agent to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Coverage of Zoladex is recommended in individuals who meet one of the following criteria:

FDA Indication(s)

1. Abnormal Uterine Bleeding. Approve for up to 2 months (total) if the individual meets the following conditions (A and B): A) Zoladex is used as an endometrial-thinning agent prior to endometrial ablation; AND

Page 1 of 3 Cigna National Formulary Coverage Policy: PA Gonadotropin-Releasing Hormone Agonists Implant - Zoladex B) The medication is prescribed by or in consultation with an obstetrician-gynecologist or a healthcare practitioner who specializes in the treatment of women’s health.

2. . Approve for 1 year if the individual meets the following conditions (A and B): A) Zoladex is used in premenopausal or perimenopausal women; AND B) The medication is prescribed by or in consultation with an oncologist.

3. . Approve for up to 6 months (total) if the individual meets the following conditions (A and B): A) Individual is ≥ 18 years of age; AND B) The medication is prescribed by or in consultation with an obstetrician-gynecologist or a healthcare practitioner who specializes in the treatment of women’s health.

4. Cancer. Approve for 1 year if the medication is prescribed by or in consultation with an oncologist.

Conditions Not Covered

Goserelin acetate (Zoladex®) is considered experimental, investigational or unproven for ANY other use including the following (this list may not be all inclusive):

1. Peripheral (also known as GnRH-independent precocious puberty). Children with peripheral precocious puberty do not respond to GnRH agonist therapy.6 Treatment is directed at removing or blocking the production and/or response to the excess sex steroids, depending on the cause (e.g., surgically removing human chorionic gonadotropin-secreting tumors or using glucocorticoids to treat defects in adrenal steroidogenesis [such as classic congenital adrenal hyperplasia]).

Background

Overview Zoladex is a gonadotropin-releasing hormone (GnRH) agonists implant.1-2

Zoladex is indicated for the following conditions:1,2 • Breast cancer, palliative treatment of advanced breast cancer in pre- and perimenopausal women (Zoladex 3.6 mg implant only). • Endometrial-thinning, use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding (Zoladex 3.6 mg implant only). • Endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy (Zoladex 3.6 mg implant only). • , in combination with for the management of locally confined Stage T2b-T4 (Stage B2-C). • Prostate cancer, palliative treatment.

Guidelines The NCCN Breast Cancer guidelines (version 6.2020 – September 8, 2020) does not note the use of Zoladex implants for advanced breast cancer.3 However, the guidelines note that GnRH agonists (e.g., Zoladex) administered prior to initiating chemotherapy protect against ovarian failure and reduce the risk of early menopause.

Central precocious puberty, also known as gonadotropin-dependent precocious puberty, is caused by early maturation of the hypothalamic-pituitary-gonadal axis.4 The standard of care for central precocious puberty is GnRH agonists. The European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society convened a consensus conference (2009) to review the use of GnRH agonists in pediatric patients with central precocious puberty.5 The panel noted that the available GnRH agonists (including leuprolide, , and implant) are effective despite different routes of administration, dosing, and duration of action. An update by the International Consortium (2019) reiterates the use of GnRH agonists (e.g.,

Page 2 of 3 Cigna National Formulary Coverage Policy: PA Gonadotropin-Releasing Hormone Agonists Implant - Zoladex leuprolide, triptorelin, and histrelin implant) for the treatment of central precocious puberty.6 GnRH agonists are generally well-tolerated in children and adolescents.

The National Comprehensive Cancer Network (NCCN) Prostate Cancer guidelines (version 3.2020 – November 17, 2020) lists Zoladex as an deprivation therapy (ADT) option for use in various settings (all category 2A): clinically localized disease, regional disease, prostate specific antigen (PSA) persistence/recurrence after radical prostatectomy (RP) or external beam radiation therapy (EBRT) [castration-naïve disease], and metastatic castration-naïve disease.7

References

1. Zoladex® 3.6 mg Implant [prescribing information]. Lake Forest, IL: TerSera Therapeutics; February 2019. 2. Zoladex® 10.8 mg Implant [prescribing information]. Lake Forest, IL: TerSera Therapeutics; February 2019. 3. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (Version 6.2020 – September 8, 2020). © 2020 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed on January 14, 2021. 4. Eugster EA. Treatment of central precocious puberty. J Endo Soc. 2019;3:965-972. 5. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009 Apr;123(4):e752-62. 6. Krishna KB, Fuqua JS, Rogol AD, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr. 2019;91:357-372. 7. The NCCN Prostate Cancer Clinical Practice Guidelines in Oncology (Version3.2020 – November 17, 2020). © 2020 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed on January 14, 2021.

Revision History

Type of Summary of Changes Review Date Revision Annual Revision No criteria changes. 01/20/2021

“Cigna Companies” refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., QualCare, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2021 Cigna.

Page 3 of 3 Cigna National Formulary Coverage Policy: PA Gonadotropin-Releasing Hormone Agonists Implant - Zoladex